About the Company
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company's rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SBBP News
Pelthos Therapeutics Establishes Board of Directors
Pelthos Therapeutics (Pelthos), a biopharmaceutical company committed to commercializing innovative, safe, and efficacious ...
Strongbridge Biopharma
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
Strongbridge Biopharma plc Announces Completion of Enrollment of Phase 3 LOGICS Study for RECORLEV® (levoketoconazole) for E...
Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant ...
Ravi Viswanathan's Net Worth
Inc., Strongbridge Biopharma plc, CVENT INC, Achaogen Inc, and INTERLEUKIN GENETICS INC. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro!
SBFM Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is ...
An Affordable And Programmable PLC
A programmable logic controller (PLC) is a computer designed to automate industrial machinery, and comes with protected interfaces and usually a specific PLC programming environment. Thus ...
Vor Biopharma Inc Ordinary Shares VOR
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Mereo BioPharma Group Plc (NASDAQ: MREO)
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases.
Mereo BioPharma Group PLC ADR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results
Warning! GuruFocus has detected 4 Warning Signs with MREO. Mereo BioPharma Group PLC (NASDAQ:MREO) released its 8-K filing on March 27, 2024, detailing the company's financial results for the full ...
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “ LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage ...
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “ LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage ...
Loading the latest forecasts...